The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,310.00
Bid: 1,300.00
Ask: 1,306.00
Change: -6.00 (-0.46%)
Spread: 6.00 (0.462%)
Open: 1,322.00
High: 1,322.00
Low: 1,302.00
Prev. Close: 1,316.00
VCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM and Q1 Interim Management Statement

12 Feb 2021 07:00

RNS Number : 8764O
Victrex PLC
12 February 2021
 
 

 

12 February 2021

Victrex plc - AGM and Q1 Interim Management Statement

'Positive start but variable improvement trend; full year expectations unchanged'

Victrex plc, an innovative world leader in high performance polymer solutions, releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting (AGM) being held today. Q1 covers the period 1 October to 31 December 2020.

Overall, the Group saw a positive start to FY 2021. Although Q1 was slightly ahead of our expectations, performance remains variable by end market. Asia is seeing the most incremental improvement on a geographic basis, with a mixed performance in Europe and the US.

For Q1 as a whole, Group revenue of £68.7m was 1% ahead of the prior year (Q1 2020: £67.7m), with Q1 Group sales volume of 883 tonnes also being 1% ahead of the prior year (Q1 2020 877 tonnes). Since the 1 October 2020, FY 2021 on a year-to-date (YTD) basis is slightly lower than the prior year, reflecting January being robust but lower than the prior year.

End market performance

Across our end-markets, trading saw an incremental improvement from the low point of H2 2020, with Electronics being notably strong as increased homeworking supports demand for a range of smart devices. Performance in Automotive, Medical and Value Added-Resellers was broadly stable compared to the prior year period, with Automotive benefiting from new application growth and some cyclical recovery, and Medical continuing to see a gradual improvement in procedures, largely in Asia. Whilst Energy saw some limited improvement from the low point of H2 2020, performance was lower than the prior year period. Aerospace remains challenging on a short-term basis.

Mega-programmes

As previously communicated, we continue to see little evidence of any material slowdown in our pipeline of 'mega-programmes'. We remain fully focused on delivering specific milestones as we move closer to greater commercialisation.

 

Financial position

Victrex retains a highly cash generative business model, with our cash position improving since the end of FY 2020. Net cash of £84.4m at 31 December 2020 excludes cash ringfenced for our Panjin VYX facility in China, in what will be a year of high capital expenditure totalling up to £50m for the Group.

Brexit, inventory and supply chain

Following the Brexit trade agreement, which took effect from January 1st 2021, the Group has seen no material issues in its supply chain. High service levels are being maintained for customers, with continued tariff free access into the EU.

Whilst our inventory levels remain high, we are on plan to unwind sales inventory through the remainder of FY 2021, which will start to benefit our working capital position.

COVID-19

 

We have sustained our proactive approach to managing the impact of COVID-19 with the safety, health and well-being of Victrex employees being our highest priority. Our COVID contingency plans remain in place and our supply chain has been unaffected, enabling us to continue to meet our customers' needs in full. Our financial position remains strong and the outlook is starting to improve as some signs of recovery emerge in several of our end markets.

 

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "This is a positive start to FY 2021 and we continue to see incremental improvement across several of our end markets.

"Nevertheless, the incremental improvement trend may remain variable and our assumptions are that we will still see a weaker first half overall, compared to H1 2020 which ended strongly. Consequently, at this early stage, our full year expectations are unchanged.

"Our priorities remain the health, safety and well-being of our employees and delivering strong service levels for our customers. With sustainable products and a strong pipeline of growth opportunities, our Polymer & Parts strategy keeps us well positioned for the medium to long-term."

Analyst & investor conference call

A conference call with management will take place this morning, Friday 12th February 2021, at 0830am GMT via +44 (0) 3333 000804 and PIN 24673921#. A replay of the call is also available at +44 (0) 333 300 0819 and PIN 301336320#.

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUARURAAUUAUR
Date   Source Headline
17th Oct 201811:23 amRNSDirector/PDMR Shareholding
28th Sep 20189:17 amRNSTotal Voting Rights
18th Sep 201812:06 pmRNSDirector/PDMR Shareholding
31st Aug 201810:52 amRNSTotal Voting Rights
22nd Aug 201812:46 pmRNSHolding(s) in Company
17th Aug 201811:31 amRNSDirector/PDMR Shareholding
31st Jul 201810:56 amRNSTotal Voting Rights
27th Jul 20184:01 pmRNSHolding(s) in Company
25th Jul 201811:16 amRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSInterim Management Statement
17th Jul 201812:47 pmRNSDirector/PDMR Shareholding
29th Jun 20189:26 amRNSTotal Voting Rights
19th Jun 20183:25 pmRNSDirector/PDMR Shareholding
1st Jun 20189:04 amRNSBlock listing Interim Review
31st May 20181:29 pmRNSTotal Voting Rights
17th May 20182:37 pmRNSDirector/PDMR Shareholding
16th May 20183:47 pmRNSDirector/PDMR Shareholding
14th May 20187:01 amRNSDirectorate Change
14th May 20187:00 amRNSHalf-year Report
1st May 201811:42 amRNSTotal Voting Rights
30th Apr 201811:40 amRNSAdditional Listing
17th Apr 20184:28 pmRNSDirector/PDMR Shareholding
28th Mar 201810:00 amRNSGroup Financial Director Update
19th Mar 20183:13 pmRNSDirector/PDMR Shareholding
1st Mar 20182:22 pmRNSTotal Voting Rights
19th Feb 20184:30 pmRNSDirector/PDMR Shareholding
12th Feb 201810:32 amRNSDirectorate Change
12th Feb 201810:30 amRNSDirectorate Change
9th Feb 201811:50 amRNSResult of AGM
9th Feb 201811:24 amRNSDirector/PDMR Shareholding
9th Feb 20187:00 amRNSAGM & Q1 IMS
7th Feb 20184:16 pmRNSHolding(s) in Company
6th Feb 20181:44 pmRNSDirectorate Change
1st Feb 201812:13 pmRNSTotal Voting Rights
25th Jan 20189:49 amRNSHolding(s) in Company
17th Jan 20184:25 pmRNSDirector/PDMR Shareholding
4th Jan 201812:06 pmRNSNomination for election of Non-executive Directors
4th Jan 201812:00 pmRNSAnnual Financial Report
29th Dec 201710:00 amRNSTotal Voting Rights
19th Dec 20174:24 pmRNSDirector/PDMR Shareholding
18th Dec 201710:08 amRNSDirector/PDMR Shareholding
8th Dec 20171:19 pmRNSDirector/PDMR Shareholding
5th Dec 201711:39 amRNSDirector/PDMR Shareholding
5th Dec 20177:01 amRNSDirectorate Change
5th Dec 20177:00 amRNSFinal Results
1st Dec 201712:51 pmRNSBlock listing Interim Review
30th Nov 20171:41 pmRNSTotal Voting Rights
27th Nov 201711:20 amRNSAdditional Listing
17th Nov 20173:57 pmRNSDirector/PDMR Shareholding
31st Oct 20179:41 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.